BioNTech price target lowered to $145 from $150 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on BioNTech (BNTX) to $145 from $150 and keeps a Buy rating on the shares. The firm says ...
Truist Financial Remains a Buy on BioNTech SE (BNTX)
Truist Financial analyst Asthika Goonewardene maintained a Buy rating on BioNTech SE (BNTX – Research Report) today. The company’s shares ...